BOSTON, April 2 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (OTC Pink Sheets: SNDY) is pleased to announce that the Company has developed a new endocoupler with an eye piece for the MammoView(TM) system. Along with its current endocoupler, it will allow the MammoView scope to be used by a majority of the video systems currently in the market place. Solos has already started to market the new endocoupler to those customers that previously could not utilize the standard endocoupler. The new MammoView Endocoupler will allow healthcare facilities to have more flexibility because it allow them to utilize any video system at their disposal.
"The new MammoView(TM) endocoupler enables us to offer the MammoView system to a wider customer base that was previously excluded because of the incompatibility of the original endocoupler," stated Bob Segersten, President of Solos Endoscopy, Inc.
Solos Endoscopy recently announced that the Company received a purchase order for its MammoView(TM) line of surgical endoscopy instruments from Sharp Healthcare, one of the leading healthcare providers in the San Diego region.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
|SOURCE Solos Endoscopy, Inc.|
Copyright©2009 PR Newswire.
All rights reserved